The Reaction Oncology Platform

The Reaction Oncology Platform is Reaction Biology’s answer to the growing demand of integrated drug discovery needs to find new cures in the fight against cancer. Our broad portfolio and global network of partners enable us to provide end-to-end service for the discovery of new cancer therapeutics by holding true to our values: quality data, quality support.

Biomarker Identification and Screening In Vivo Oncology Cell-based Oncology Cardiac Safety Assessment ADME-Tox Mode of Action Analysis Biophysical Analysis Medicinal Chemistry Integration Compound Screening Cascade Primary Screening Assay Development Protein Production Target Validation Preclinical Candidate Lead Optimization Hit-to-Lead Hit Identification Target Research

Our Promise

20 years of experience in creating new small molecules against cancer enable a science-driven approach warranting high success rates. Your team will consist of our top-level scientists available for direct communication to provide innovative research solutions custom-tailored to your project.

As a medium-sized CRO with 120 employees, we are large enough to provide consistent end-to-end solutions and small enough to welcome projects of any size. We care about your research projects because your work and our relationship are important to us. 

Why partner with us?

Comprehensive: A broad portfolio of 2000+ assays gives your project a head start.

Collaborative: Our clients work directly with our team of top-level scientists. A scientific program manager facilitates the progress of the project, ensures timelines are met, and assists with the communication between teams. 

Consistent: Full coverage of drug efficacy testing capabilities, including biochemical, biophysical, cellular, and in vivo models, ensuring data consistency within your program.

Cross-Disciplinary: We work with the best partners providing medicinal chemistry support as well as ADME-Tox and cardiac safety services. All under one single contract.

Client Service: We pride ourselves on responsive customer service - providing continuity with a dedicated senior scientist team. 

The Goal

Our goal is the creation of potent drug candidates to meet the needs of tomorrow's cancer patients. 

The Reaction Oncology Platform integrates various aspects of drug discovery into one program. What makes a successful program?

The ability for informed decision-making by providing potency and functional data allows insight into the mechanism of compound-target interaction. 

Cancer is an incredibly diverse disease, with many patients often not responding to new drugs. Finding predictive biomarkers ensures that drug testing is performed in cell and animal models that work and paves the way for patient stratification during the clinical phase.

The safety and bioavailability of new drug candidates are vital for progressing into the regulatory phase. Therefore, our full coverage of cardiac liability assays and partnership with an expert ADME-tox firm ensures the creation of drugs with favorable pharmacologic and toxicologic profiles.

Your Team

  • Your team comprises our top-level scientists, including chemists, biologists, and pharmacologists.
  • One scientific program manager will advance your project through the various discovery phases and manage timelines and expectations.
  • Our scientific leaders are available for direct consultation already in the planning phase of new projects.

Our Research Facilites

Reaction Biology Corporation, Malvern, USA (Headquarter)

Location: Malvern, PA, US

Research capabilities: Assay development, biochemical and biophysical screening, cell-based assays

Size: 28,000 sqft; 75 employees

Instrumentation:

  • Echo acoustic liquid handler
  • Biacore 8K/8K+ SPR spectrometers
  • TA instruments nano ITC
  • NanoTemper Monolith NT.115 pico
  • BioRad BCFX384 real-time PCR detection system
  • IncuCyte S3 Live-Cell Analysis Systems
  • Envision Multilabel Plate Reader
Reaction Biology Europe GmbH, Freiburg, Germany

Location: Freiburg, Germany

Research capabilities: Assay development, biochemical screening, cell-based oncology assays, in vivo pharmacology

Size: 16,000 sqft; 53 employees

Instrumentation:

  • Perkin Elmer IVIS Spectrum In Vivo Imager
  • Guava EasyCyte flow cytometer
  • MESO QuickPlex SQ120 multiplexing instrument
  • GelCount colony and spheroid counter
  • Envision multilabel plate reader
  • Odyssey CLx infrared imaging system
  • Flow cytometry and cell sorting core facility

Our Key Partners

Pharmacore Labs

  • Cardiac safety assessment
  • Ion Channel Drug Discovery

~ 20 employees

Pharmacore Labs

  • Cardiac safety assessment
  • Ion Channel Drug Discovery

~ 20 employees

Pharmacore Labs

Symeres

  • Medicinal Chemistry
  • Computational Chemistry
  • Synthetic Chemistry

Admescope
a Symeres company

  • In vitro ADME
  • In vivo DMPK
  • In vitro Toxicology

~  500 employees

Symeres

  • Medicinal Chemistry
  • Computational Chemistry
  • Synthetic Chemistry

Admescope
a Symeres company

  • In vitro ADME
  • In vivo DMPK
  • In vitro Toxicology

~  500 employees

Symeres

Medinoah

  • Medicinal Chemistry
  • PROTAC Platform
  • cGMP Production

~ 200 employees

Medinoah

  • Medicinal Chemistry
  • PROTAC Platform
  • cGMP Production

~ 200 employees

Medinoah

4HF Biotec

  • Bioinformatics support
  • Cancer Mining Database

~ 5 employees

4HF Biotec

  • Bioinformatics support
  • Cancer Mining Database

~ 5 employees

4HF Biotec